The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital discuss the opportunties, regulatory challenges and uncertainty surrounding AI.

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and ...

Analyst reactions to Donald Trump’s election victory were mixed Wednesday, with potential positives including an FTC that is ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated ...